Your browser doesn't support javascript.
Faecal immunochemical tests safely enhance rational use of resources during the assessment of suspected symptomatic colorectal cancer in primary care: systematic review and meta-analysis.
Pin-Vieito, Noel; Tejido-Sandoval, Coral; de Vicente-Bielza, Natalia; Sánchez-Gómez, Cristina; Cubiella, Joaquín.
  • Pin-Vieito N; Gastroenterology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
  • Tejido-Sandoval C; Instituto de Investigacíon Sanitaria Galicia Sur, Ourense, Spain.
  • de Vicente-Bielza N; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ourense, Spain.
  • Sánchez-Gómez C; Biochemistry, Genetics and Immunology, Faculty of Biology, University of Vigo, Vigo, Spain.
  • Cubiella J; Gastroenterology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Gut ; 71(5): 950-960, 2022 05.
Article in English | MEDLINE | ID: covidwho-1784858
ABSTRACT

OBJECTIVE:

Implementation of faecal immunochemical tests (FIT) as a triage test in primary healthcare may improve the efficiency of referrals without missing cases of colorectal cancer (CRC). We aim to summarise the performance characteristics of FITs for CRC in symptomatic patients presenting to primary healthcare.

DESIGN:

We performed a systematic literature review of Medline and EMBASE databases from May 2018 to November 2020. Previous related systematic searches were also adapted to this aim and completed with reference screening. We identified studies performed on adult patients consulting for abdominal symptoms in primary care which reported data such that the FIT diagnostic performance parameters for CRC could be obtained. Bivariate models were used to synthesise available evidence. Meta-regression analysis was performed to evaluate the causes of heterogeneity.

RESULTS:

Twenty-three studies (69 536 participants) were included (CRC prevalence 0.3%-6.2%). Six studies (n=34 691) assessed FIT as rule in test (threshold of ≥150 µg Hb/g faeces) showing a sensitivity of 64.1% (95% CI 57.8% to 69.9%) and a specificity of 95.0% (95% CI 91.2% to 97.2%). A threshold of 10 µg/g (15 studies; n=48 872) resulted in a sensitivity of 87.2% (95% CI 81.0% to 91.6%) and a specificity of 84.4% (95% CI 79.4% to 88.3%) for CRC. At a 20 µg Hb/g faeces threshold (five studies; n=24 187) less than one additional CRC would be missed per 1000 patients investigated compared with 10 µg Hb/g faeces threshold (CRC prevalence 2%).

CONCLUSION:

FIT is the test of choice to evaluate patients with new-onset lower gastrointestinal symptoms in primary healthcare.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colorectal Neoplasms / Early Detection of Cancer Type of study: Diagnostic study / Experimental Studies / Observational study / Reviews / Systematic review/Meta Analysis Limits: Adult / Humans Language: English Journal: Gut Year: 2022 Document Type: Article Affiliation country: Gutjnl-2021-324856

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Colorectal Neoplasms / Early Detection of Cancer Type of study: Diagnostic study / Experimental Studies / Observational study / Reviews / Systematic review/Meta Analysis Limits: Adult / Humans Language: English Journal: Gut Year: 2022 Document Type: Article Affiliation country: Gutjnl-2021-324856